Post-translational modifications (PTMs) play essential roles in the regulation of biological reactions. Among them, Ub and Ub-like modifiers such as SUMO are being found to have an increasingly prominent role in DNA replication and repair, in which they function in a coordinated manner. This synergy is best exemplified in the clamp loader proliferating cell nuclear antigen (PCNA), which is ubiquitinated and/or SUMOylated in response to DNA damage; these modifications promote loading of alternative DNA polymerases or template switching at replication forks 1,2 . Moreover, PCNA assembles an E3 ubiquitin ligase complex that regulates origin licensing and limits rereplication 3 . Finally, PCNA ubiquitination is counteracted by the action of the ubiquitin-specific protease (USP) USP1, which deubiquitinates PCNA, thereby preventing excessive loading of translesion synthesis (TLS) polymerases 4 , and also acts on FANCD2-FANCI complexes, thereby limiting DNA-damage responses 5, 6 . Nevertheless, PCNA is just one example that illustrates the dynamic nature of Ub and SUMO modifications at sites of DNA replication.
Post-translational modifications (PTMs) play essential roles in the regulation of biological reactions. Among them, Ub and Ub-like modifiers such as SUMO are being found to have an increasingly prominent role in DNA replication and repair, in which they function in a coordinated manner. This synergy is best exemplified in the clamp loader proliferating cell nuclear antigen (PCNA), which is ubiquitinated and/or SUMOylated in response to DNA damage; these modifications promote loading of alternative DNA polymerases or template switching at replication forks 1, 2 . Moreover, PCNA assembles an E3 ubiquitin ligase complex that regulates origin licensing and limits rereplication 3 . Finally, PCNA ubiquitination is counteracted by the action of the ubiquitin-specific protease (USP) USP1, which deubiquitinates PCNA, thereby preventing excessive loading of translesion synthesis (TLS) polymerases 4 , and also acts on FANCD2-FANCI complexes, thereby limiting DNA-damage responses 5, 6 . Nevertheless, PCNA is just one example that illustrates the dynamic nature of Ub and SUMO modifications at sites of DNA replication.
SUMO-targeted Ub ligases (STUbLs) are important mediators of the interplay between SUMO and Ub 7 . In mammals, RNF4 is the main chromatin-related STUbL, and it has roles in double-strand break (DSB) repair and DNA replication [8] [9] [10] . Of note, chromatin imposes a barrier to the access of PTM modifiers and readers 11 , and recent studies have revealed a role of the chaperone p97 in extracting ubiquitinated substrates from chromatin. Together with its cofactor DVC1 (Spartan), p97 extracts TLS polymerases bound to ubiquitinated PCNA from chromatin during DNA replication 12, 13 and removes active FANCI-FANCD2 complexes after genotoxic stress 14 . USP11 has recently been identified as a SUMO2 deubiquitinase that acts on SUMOylated promyelocytic leukemia protein (PML) 15 . In contrast to STUbLs, no SUMO deubiquitinases (SDUBs) with an active role in DNA replication or repair have been identified.
Beyond the specific roles of individual PTMs, it has been proposed that SUMO regulates signaling networks through the collective modification of factors in a common pathway 16 . Supporting this view, proteomic analyses have revealed global changes in SUMOylation in response to stress conditions, including replication stress [17] [18] [19] [20] [21] . Through the method of isolation of proteins on nascent DNA (iPOND) 22 coupled to MS, we have recently shown that chromatin surrounding replisomes shows an overall enrichment of SUMO peptides that is concomitant with lower levels of ubiquitination 23 . A comprehensive iPOND-MS analysis has recently confirmed this observation 24 . How such SUMO-rich, Ub-poor chromatin is built around replisomes remains unknown, but we reasoned that the low levels of Ub might be related to the presence of deubiquitinating activities at replication forks.
Here we sought to investigate the role of USPs, particularly USP7, in DNA replication. Early work has shown that depletion of USP7 leads to a loss of MDM2 and a concomitant upregulation of p53 (refs. 25,26) . On the basis of these findings, chemical inhibitors of USP7 are being developed as anticancer agents, because of their capacity to stabilize p53 (refs. 27-29) . However, USP7 is essential for mouse development, and USP7 deficiency cannot be rescued by p53 deletion 30 . Moreover, a growing number of targets beyond MDM2 and p53 are being identified for USP7 (refs. 31-42) . In addition, recent evidence has also demonstrated that USP7 has a role during DNA-replication termination, by facilitating unloading of the MCM complex 43 . From these data, we hypothesized that USP7 might regulate DNA replication, and hence we sought to determine whether this deubiquitinase (DUB) might be involved in the creation of a SUMO-rich and Ub-poor environment in the replisome. Our data show that USP7 is enriched at sites of DNA replication and is necessary for replication-fork progression and the firing of new origins. Proteomic identification of USP7 targets revealed several peptides on the surface of SUMO2, and our in vitro and in vivo data confirmed the role of USP7 as a replication-associated SDUB. Importantly, USP7 inhibition or genetic deletion abrogated the local concentration of SUMO at replication forks, thus suggesting that USP7 is the first known factor that regulates the overall concentrations of Ub and SUMO PTMs at sites of DNA replication.
RESULTS

USP7 activity is essential for DNA replication
To determine the relative abundance of USPs around replisomes we performed iPOND experiments coupled to isobaric tags for absolute and relative quantitation (iTRAQ) and evaluated their presence in nascent and mature chromatin ( Fig. 1a and Supplementary Table 1) . Among the different USPs enriched in the replisome fraction, USP7 was notable for several reasons. First, USP7 is essential at the embryonic-stem-cell stage, owing to impaired proliferation 30 . Second, USP7 regulates the stability of known components of the replisome, such as UHRF1 and DNMT1 (refs. [44] [45] [46] , and proteomic analyses have revealed an interaction between USP7 and members of the MCM complex 47 . We confirmed that USP7 immunoprecipitation recovered MCM4, and this interaction was not affected by USP7 inhibition (Fig. 1b) . The interaction was specific, because we detected no PCNA in USP7 pulldowns. In control experiments, USP7 interacted with SCML2, as described previously 36 . Together, these data show that USP7 is a replisome-associated USP.
Next, we sought to explore the function of USP7 in DNA replication by using the specific inhibitor P22077, which preferentially inhibits USP7 in vitro and in vivo, and exhibits some in vitro activity against USP47 (ref. 27 ). Treatment of HCT116 cells with P22077 led to a dose-dependent reduction in 5-ethynyl-2′-deoxyuridine (EdU) incorporation together with an increase in phosphorylated histone H2AX (γH2AX), as measured by high-throughput microscopy (HTM) (Fig. 1c,d) . Time-course experiments revealed a fast blockade of replication (Supplementary Fig. 1a ) preceding γH2AX accumulation (Supplementary Fig. 1b) . These data suggest that USP7 inhibition generates replicative stress. Consistently with this conclusion, treatment with P22077 led to PCNA monoubiquitination and subsequent CHK1 phosphorylation (Fig. 1e) . We detected ATM-dependent phosphorylation of RPA at later times, a result indicative of the formation of DSBs (Fig. 1e) . In contrast, as expected, p53 ubiquitination decreased, and we observed no changes in the levels of p21, p53 or MCM4 at early times ( Supplementary Fig. 1c) . Moreover, USP7 inhibition led to a similar reduction of EdU and an increase of γH2AX in wild-type (WT) and p53-deficient mouse embryonic fibroblasts (MEFs) ( Fig. 1f and Supplementary Fig. 2 ), thus confirming that the effects of USP7 inhibition on DNA replication are independent of p53. Two additional USP7 inhibitors, P5091 (structurally related to P22077) 28 and HBX19818 (structurally unrelated to P22077 but A r t i c l e s npg A r t i c l e s also selective toward USP7) 29 , reduced EdU incorporation and led to replication stress in HCT116 cells, thus confirming that the effect was not particular to P22077 (Supplementary Fig. 3a-d) . Importantly, USP7 inhibition generated replication stress in both WT cells and RAD18-deficient HCT116 cells, which cannot ubiquitinate PCNA (Supplementary Fig. 3e ). Collectively, these data establish that USP7 is present in the vicinity of replisomes and that its activity is required to sustain active DNA replication and prevent replication stress independently of PCNA ubiquitination or p53.
USP7 regulates fork progression and origin firing
To understand how USP7 regulates DNA replication, we analyzed fork progression and origin activity in stretched DNA fibers. We cultured HCT116 cells in the presence of USP7 inhibitors for 15 min and then sequentially treated them with chlorodeoxyuridine (CldU) and iododeoxyuridine (IdU) to label replicating DNA. Treatment with three different USP7 inhibitors led to a strong reduction in the speed of ongoing replication forks ( Fig. 2a-d) . Challenges that reduce the speed of replication forks, such as oncogene overexpression or exposure to genotoxic drugs, lead to the activation of additional 'dormant' origins as compensation 48, 49 . In contrast, USP7 inhibition with any of the three drugs not only decreased fork speed but also reduced the firing of new origins (Fig. 2e-g ). Moreover, in 293T-REx cells with doxycycline-inducible overexpression of USP7 (Fig. 2h) , we observed that the percentage of cells in S phase and the amount of origin firing increased 24 h after USP7 induction ( Supplementary Fig. 4 ). These monomers showed that USP7 expression significantly counteracted the reduction in fork speed in response to P22077, thus further supporting that the effects of the inhibitors in DNA replication were due to USP7 (Fig. 2i) . Hence, USP7 activity promotes origin firing and replication-fork progression in human cells.
Proteomic analyses identify SUMO2 as a USP7 target
To investigate how USP7 regulates DNA replication, we searched for new substrates of this DUB on chromatin. We used a recently developed pipeline based on the immunoprecipitation of ubiquitinated peptides with an antibody that recognizes the diglycine remnant left after tryptic digestion of the ubiquitin moiety (di-Gly method) 50 . We treated HCT116 cells with P22077 for 2 h, purified the chromatin fraction and analyzed ubiquitinated peptides with di-Gly-proteomics (Supplementary Table 2 ). At this time point, although DNA replication was severely affected, there was still no phosphorylation of RPA2, thus minimizing changes secondary to fork collapse and DSB formation. Within a plot of the results, we identified a region containing ubiquitinated peptides that were enriched after USP7 inhibition in two independent experiments (Fig. 3a) . As expected, this region 
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A r t i c l e s included several known targets of USP7 and, consistently with our previous results, it also showed a mild increase of ubiquitination of PCNA at K164 (Fig. 3a) . Interestingly, among the ubiquitination sites enriched after USP7 inhibition, we also detected four different lysines in SUMO2 (K7, K11, K21 and K33) ( Fig. 3a) , all of which mapped to the surface of the protein (Fig. 3b) .
For a specificity control, we carried out similar experiments in chromatin extracts from HCT116 cells treated with the USP1 inhibitor ML323 (ref. 51 ). USP1, the DUB that removes PCNA monoubiquitination 4 , was also enriched at replisomes in our iPOND experiments (Fig. 1a) , consistently with previous findings 52 . Furthermore, USP1 inhibition strongly increased PCNA K164 ubiquitination in two independent experiments, whereas we observed no effect on most known USP7 substrates (Fig. 3c) . Importantly, none of the lysines on SUMO2 with increased ubiquitination in response to P22077 were ubiquitinated after USP1 inhibition (Fig. 3c) . These data indicate that the effects of USP7 inhibition on SUMO2 are selective rather than being general effects of USPs present in chromatin.
USP7 deubiquitinates SUMO2 in vitro and in vivo
We next evaluated whether USP7 was able to deubiquitinate SUMO2 chains in vitro. We ubiquitinated poly-SUMO2 chains, comprising three to eight SUMO2 monomers, with recombinant His-RNF4 (Fig. 4a) . After purifying SUMO2 chains with nickel-nitrilotriacetic acid (Ni-NTA) agarose chromatography, we incubated ubiquitinated poly-SUMO2 with either recombinant USP7 or USP1 and UAF1 and analyzed the products of the reactions by western blotting (WB) (Fig. 4a-d) . His-RNF4 preferentially polyubiquitinated long poly-SUMO2 chains, as previously described 53 (Fig. 4b , comparison of -to C), but also catalyzed monoubiquitination of poly-SUMO chains comprising three to five SUMO2 molecules (thus forming Ub-(SUMO2) 3-5 ) (Fig. 4b) . Increasing amounts of USP7 efficiently deubiquitinated Ub-(SUMO2) 3-5 , whereas we observed no effect in the presence of USP1 (Fig. 4b) . Importantly, we confirmed the identity of ubiquitinated SUMO2 bands by MS, which identified SUMO2 peptides containing the di-Gly ubiquitin remnant arising from tryptic digestion (Supplementary Fig. 5a,b) . Moreover, some of the lysines of SUMO2 that underwent USP7-dependent deubiquitination in vitro corresponded to lysines exhibiting increased ubiquitination after USP7 inhibition in vivo (K11 and K33).
Highly ubiquitinated poly-SUMO2 chains accumulated as highmolecular-weight species that showed poor entry into the gel (Fig. 4c , lane C). Incubation with USP7, but not USP1, also reduced the size of these highly ubiquitinated species (Fig. 4c) , thus indicating that USP7 can target both mono-and polyubiquitinated SUMO2 chains. Consistently with this conclusion, recombinant USP7 (and USP1) cleaved K48 and K63 poly-Ub chains (Supplementary Fig. 5c ). In contrast, USP7 had no activity against nonubiquitinated poly-SUMO2 chains (Supplementary Fig. 5d ). Thus, our results confirm that USP7 is a SUMO2 deubiquitinase that removes mono and polyubiquitin from SUMO2 chains.
Finally, to determine whether USP7 also deubiquitinates SUMO2 in vivo, we first treated U2OS cells with P22077 and measured the levels of chromatin-bound SUMO2 and SUMO3 (SUMO2/3) by immunofluorescence (IF) after removal of the nuclear soluble proteins by extraction with a mild detergent. These analyses revealed an increase in chromatin-bound SUMO2/3 after USP7 inhibition ( Fig. 4e and  Supplementary Fig. 6a ). Subcellular fractionation of HCT116 extracts and subsequent WB confirmed that the action of USP7 is restricted to chromatin. Whereas we detected no change in the cytosol, we observed accumulation of SUMO2/3-modified proteins in the nuclear soluble fraction and particularly the chromatin fraction after USP7 inhibition (Fig. 4f) . Importantly, we did not observe this accumulation of chromatin-bound SUMO2/3 in response to hydroxyurea treatment, thus indicating that it is a specific effect of USP7 inhibition and not a general response to replication stress (Supplementary Fig. 6b ).
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A r t i c l e s after USP7 inhibition were also ubiquitinated, we transfected 293T cells with a plasmid encoding His-Ub. After immunoprecipitating ubiquitinated proteins with Ni-NTA resin, we measured the levels of SUMOylated proteins in the input and the pulldown (Fig. 4g) .
As expected, the inhibition of the proteasome with MG132 led to a strong accumulation of SUMOylated proteins in the input, whereas inhibition of USP7 had a much milder effect (Fig. 4g) . Analysis of the pulldown material revealed a strong increase in SUMOylated and ubiquitinated proteins after inhibition of either the proteasome or USP7 (Fig. 4g) . Together, these data show that USP7 is an SDUB, and its inhibition results in the accumulation of chromatin-bound SUMOylated proteins that are also ubiquitinated.
The segregase p97 cooperates with USP7 on chromatin Whereas ubiquitination usually targets proteins for degradation, we observed that USP7 inhibition leads to the accumulation of ubiquitinated proteins on chromatin. Recent evidence has shown that in order for chromatin-bound ubiquitinated proteins to be degraded, they first need to be extracted by the p97 segregase 54 . We thus analyzed whether p97 inhibition might further increase the accumulation of SUMOylated and ubiquitinated proteins on chromatin that occurs after USP7 inhibition. Exposure of HCT116 cells to the recently described p97 inhibitor NMS873 (ref. 55) did not affect the levels of SUMOylated proteins but, as expected, increased the levels of chromatin-bound ubiquitinated proteins (Supplementary Fig. 7a,b) . In contrast, USP7 inhibition increased the levels of both SUMOylated and ubiquitinated proteins on chromatin, and the combined inhibition of USP7 and p97 enhanced this accumulation ( Supplementary  Fig. 7a,b) . In addition, treatment with P22077 and NMS873 resulted in a further reduction in EdU incorporation than did either treatment alone (Supplementary Fig. 7c ). Together, these data suggest that USP7 targets SUMOylated proteins at replisomes and limits their ubiquitination. Ubiquitinated factors then become substrates for p97, and p97 subsequently extracts them from chromatin. Consistently with this view, p97 inhibition results in further accumulation of chromatin-bound SUMO2 after exposure to USP7 inhibitors. This model suggests that USP7 facilitates the concentration of SUMOylated proteins around replisomes by limiting their ubiquitination and subsequent extraction by the p97 segregase.
USP7 inhibition reduces SUMO abundance at replisomes
As mentioned above, using iPOND, we have recently described that the chromatin surrounding replisomes is enriched in SUMO 23 . 
A r t i c l e s
Consistently with this finding, previous IF studies have shown that SUMO2/3 colocalize with PCNA during S phase 56 . We thus tested whether USP7 inhibition affected the enrichment of SUMO at sites of DNA replication. P22077 treatment of primary MEFs led to the accumulation of chromatin-bound SUMO2/3 conjugates (Fig. 5a) , similarly to its effects on human cells. Strikingly, although USP7 inhibition increased the amount of SUMOylated proteins on chromatin, as confirmed by IF, it disrupted their localization to PCNA foci (Fig. 5b) .
In contrast, USP7 inhibition did not alter the colocalization also observed between SUMO2/3 and PML (Fig. 5c) , thus supporting that the delocalization of SUMOylated proteins is specific to replication factors. To confirm this observation, we carried out iPOND experiments in the presence of USP7 inhibitors, under conditions that did not completely abolish DNA replication. Whereas, as expected, SUMO2/3 was enriched in nascent DNA (EdU fraction) compared with mature chromatin (thymidine fraction), USP7 inhibition reduced the enrichment of SUMO2/3 around replisomes (Fig. 5d , comparison of EdU and EdU-P22). Together with our previous results, these data show that USP7 inhibition leads to the ubiquitination of SUMOylated proteins, which in turn drives these SUMOylated factors away from the environs of the replication fork.
USP7 deletion recapitulates the effects of USP7 inhibitors
Finally, we sought to obtain genetic confirmation of our findings. To this end, we used previously described USP7 conditional knockout (Usp7 lox/lox ) MEFs 30 . Infection of immortalized Usp7 lox/lox MEFs with adenoviruses expressing Cre recombinase (AdCre) led to the loss of USP7 protein after 4 d (Fig. 6a) . DNA fiber assays revealed reduced fork progression and origin firing after USP7 deletion (Fig. 6b,c) . Importantly, and similarly to the effects of USP7 inhibitors, infection of Usp7 lox/lox MEFs with AdCre led to the accumulation of SUMO2/3-modified chromatin-bound proteins, as assessed by WB (Fig. 6d) . Moreover, IF experiments in USP7-deleted MEFs confirmed the increase of chromatin-bound SUMO2/3 conjugates as well as the loss of colocalization of SUMO2/3 with PCNA (Fig. 6e) . In a control experiment, AdCre infection of WT MEFs did not significantly affect USP7 levels, fork progression, origin firing or the levels of chromatin-bound SUMO2/3 ( Supplementary Fig. 7d-g ). Together with the data for multiple USP7 inhibitors, these data provide genetic evidence that USP7 is an SDUB essential for mammalian DNA replication and identify USP7 as the first factor required to maintain a SUMO-rich environment surrounding replication forks.
DISCUSSION
Here we presented what is, to our knowledge, the first proteomic analysis of the USP7 targetome and compared it to that of USP1, another DUB essential for DNA replication and having a role in PCNA deubiquitination 4 . Our results illustrate that USPs concentrated around replisomes have distinct specific substrates, rather than acting indiscriminately on ubiquitinated proteins. On the one hand, USP1 acts on PCNA and has no effect on USP7 targets. On the other hand, inhibition of USP7 increases the ubiquitination of its substrates and results in only a mild increase in PCNA ubiquitination, which is secondary to the stalling of replication forks. Our di-Gly proteomics analysis also led to the identification of SUMO2 as a USP7 target, which we further confirmed both in vivo and in vitro with purified components. Although the existence of STUbLs has been known for years 7 , no SDUBs had been identified until recently. USP11 has very recently been identified as a SUMO2 deubiquitinase that acts on SUMOylated PML 15 . However, USP11 is not enriched at replisomes, and the reported role of USP11 seems to be restricted to the modulation of PML. In contrast, USP7 inhibition leads to a generalized accumulation of SUMOylated and ubiquitinated proteins on chromatin; thus, USP7 is the main chromatin-bound SDUB. We have recently described that chromatin near replisomes is rich in SUMO and poor in Ub-modified proteins 23 . The general changes that we observed in many modified factors are consistent with results from previous studies revealing how SUMO-based regulation of biological pathways operates through the collective modification of multiple proteins at several sites 16 . However, how a localized PTM environment is maintained at replication forks was not previously understood, and we proposed a model based on our data (Fig. 7) . Consistently with results from recent proteomic reports 17, 19, 21 , we found that several factors involved in DNA replication are SUMOylated during S phase, thus potentially facilitating their concentration around replication forks. Our data show that the continuous action of USP7, enriched near replication forks, maintains a low level of ubiquitination of these factors (Fig. 7a) . After USP7 inhibition, SUMOylated factors are quickly ubiquitinated, thus leading to their accumulation on chromatin away from replisomes (Fig. 7b) . Identifying the individual targets of USP7 that are both SUMOylated and ubiquitinated will require further work, but, regardless of any specific target, the collective displacement of DNA-replication factors from replication forks may explain the dramatic effect of USP7 inhibition on both fork rate and origin firing. Moreover, the discovery of USP7 as a replisome-associated SDUB provides an explanation 
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A r t i c l e s for the SUMO-rich and Ub-poor environment found around replisomes and constitutes the first example, to our knowledge, of a factor involved in the regulation of this coordinated PTM balance. In addition to being relevant to basic understanding of how DNA replication works, our findings may also be applicable in a biomedical context. On the basis of the finding that USP7 depletion leads to the stabilization of p53 (refs. 25,26) , several specific USP7 inhibitors have been developed [27] [28] [29] , and their clinical potential is currently being assessed 57 . However, the embryonic lethality of USP7 deletion is not rescued by the absence of p53 and correlates with a loss of proliferation rather than with an increase in apoptosis 30 . Extending previous reports that have shown a role of USP7 in S phase in processes such as the unloading of the MCM helicase 43 or the regulation of DNMT1 (refs. 44,45), we found that USP7 has an essential role in the basic progress of DNA replication by regulating fork speed and origin firing. In addition, we also found that USP7 inhibitors generate replication stress, which we believe can substantially contribute to the cytotoxic effects of these drugs. Importantly, the effects of USP7 inhibitors on DNA replication and replication stress are unaffected by the loss of p53. In fact, the toxic effects of reagents that generate replication stress, such as ATR inhibitors, are actually higher in p53-deficient cells, owing to the enhanced S-phase entry of these cells 58 . Considering all of the above, we propose that the toxicity of USP7 inhibitors is, at least in part, due to their effects on DNA replication which would be aggravated, if anything, in cells lacking p53.
In summary, we revealed that USP7 is a replisome-associated DUB that counteracts ubiquitination at sites of DNA replication. The action of USP7 helps to maintain a high concentration of SUMOylated factors around replication forks. After USP7 inhibition, SUMOylated proteins are collectively displaced away from the replisome, thus fully abrogating DNA replication by limiting fork progression and the firing of new origins. These findings shed light on the essential nature of USP7 in mammals and should be considered in the development of USP7 inhibitors for use in anticancer therapy.
METHODS
Methods and any associated references are available in the online version of the paper. Accession codes. Mass spectrometry proteomics data related to this manuscript have been deposited in the ProteomeXchange Consortium via the Proteomics Identifications (PRIDE) partner repository under dataset identifier PXD002408. 
ONLINE METHODS
Cell lines, extract preparation, transfections and treatments. HCT116 (Johns Hopkins University), HeLa and U2OS cells (ATCC) and 293T-Rex (Invitrogen) cells were grown in DMEM with 10% FBS, penicillin (100 IU/ml), streptomycin (100 mg/ml) and glutamine (300 mg/ml). USP7 cKO MEFs (kind gift of W. Gu) were grown in 15% FBS, penicillin (100 IU/ml), streptomycin (100 mg/ml) and glutamine (300 mg/ml). P22077 (Tocris), P5091 (Tocris), HBX19818 (Chem Scene), ML323 (Axon), and MG132 (Sigma) were dissolved in DMSO, and cells were incubated in the presence of the inhibitor or an equivalent amount of DMSO.
All cell lines were routinely tested for mycoplasma. Whole cell extracts were prepared by lysing cells in 50 mM Tris, pH 7.5, 8 M urea, and 1% CHAPS. Cytosolic and nuclear extracts were prepared as previously described 59 , and the chromatin fraction was then extracted in 50 mM Tris, pH 7.5, 8 M urea, and 1% CHAPS. For immunoprecipitation, nuclei were resuspended in high-salt buffer containing 600 mM NaCl, and the chromatin was sheared with short sonication.
Stable transfection of 293T-REx cells was performed with Lipofectamine 2000 (Invitrogen) according to the manufacturer's instructions. One day after transfection, the medium was replaced, and the following day the cells were trypsinized and seeded at a 1:10 dilution. The next day, 5 µg/ml blasticidin, 2 µg/ml puromycin (InvivoGen) and 100 µg/ml Zeocin (Invitrogen) were added to select resistant clones. The expression of the recombinant proteins was induced by addition of 1 µg/ml doxycycline for 24 h.
Antibodies and plasmids. Antibodies against USP7 (Bethyl, A300-033A), MCM4 and MCM7 (refs. 49, 60, 61) , PCNA (Santa Cruz, sc-56), SCML2 (ref. 62 ), Chk1 (Novocastra, NCL-Chk1) 63 , Chk1-S345P (Cell Signaling, 2348S), RPA2 (Abcam, ab2175), RPA2-S4/S8P (Bethyl, A300-245A), MEK2 (BD Biosciences Pharmingen, 610236), SUMO2/3 (MBL, M114-3), ubiquitin (Cell Signaling, 3933), histidine (Rockland, 600-401-382), H2A (Cell Signaling, 3636), γH2AX (Millipore, 05-636), CDK2 (Santa Cruz, M2, sc-163), p21 (Cell Signaling, 2947), PML (Santa Cruz, sc-5621) and p53 (Santa Cruz, DO-1, sc-126) were used for western blot analysis, immunoprecipitation and immunofluorescence. Validation for the application of these antibodies can be found on the manufacturers' websites or in the indicated references. Original images of gels and blots used in this study can be found in Supplementary Data Set 1. The cDNA encoding human USP7 was cloned in the pINTO plasmid 64 with BamHI and XhoI restriction sites.
iPOND We followed the iPOND protocol described in ref. 23 . 1.5 × 10 8 HeLa cells (per condition) were plated the day before the experiment. On the following day, 10 µM EdU (Invitrogen) was added to the medium for 10 min. For USP7 inhibition, we incubated the cells for 15 min with 50 µM P22077 before the addition of EdU. For the chase condition, the EdU treatment was followed by three washes in PBS and a 1-h incubation in medium containing 10 µM thymidine (Sigma-Aldrich). Cells were fixed with 1% formaldehyde for 15 min, the reaction was stopped with glycine, and then cells were scraped from the plates, permeabilized (0.25% Triton X-100 in PBS, 30 min at room temperature), and subjected to the Click-iT reaction with Biotin Azide (Invitrogen). Cell lysis (1% SDS in 50 mM Tris, pH 8) and sonication followed. For each condition, 35 × 10 8 cells were resuspended in 7 ml of lysis buffer and sonicated with a Bioruptor (Diagenode) for 20 min in 30-s on/off cycles at high intensity. Finally, EdU-biotin-labeled DNA was pulled down with 250 µl streptavidin-agarose beads (Novagen) at 4 °C for 20 h. The beads were washed twice with lysis buffer and 1 M NaCl and eluted in 100 µl of 25× NuPAGE LDS Sample Buffer (Invitrogen) containing 10% β-mercaptoethanol (25 min at 95 °C).
DNA fiber analysis. Exponentially growing cells were pulse-labeled with 50 µM CldU (15 min) and then by 250 µM IdU (15 min). Labeled cells were collected, and DNA fibers were spread in buffer (0.5% SDS, 200 mM Tris, pH 7.4, and 50 mM EDTA). For immunodetection of labeled tracks, fibers were incubated with primary antibodies (for CldU, rat anti-BrdU (Abcam, ab6326); for IdU, mouse anti-BrdU (BD Biosciences, 347580)) and developed with secondary antibodies conjugated to Alexa dyes. Mouse anti-ssDNA antibody (Millipore, MAB3034) was used to assess fiber integrity. Slides were examined with a Leica DM6000 B microscope, as described previously 65 . The conversion factor used was 1 µm = 2.59 kb (ref. 66) . In each assay, 200-300 tracks were measured to estimate fork rate, and 300-500 tracks were analyzed to estimate the frequency of origin firing (first label origins-green-red-green-are shown as a percentage of all red (CldU-labeled) tracks) 67 . Validation for the application of these antibodies can be found in the manufacturers' websites.
In vitro ubiquitination of poly-SUMO2 chains. 2.5 µg of (SUMO2) 3-8 chains (Boston Biochem) was incubated with 50 nM His-UBE1 (Boston Biochem), 1 µM His-HA-UbcH5a (Millipore), 1 µM His-RNF4 (Genwaybio) and 3 µM ubiquitin (Boston Biochem) in 100 mM Tris, pH 7.5, 400 mM NaCl, 10 mM MgCl 2 , 6 mM ATP, 0.2% IGEPAL CA630, and 0.2 mM DTT (100 µl per reaction). After 30 min at 37 °C, 10 µl of Ni-NTA agarose resin (Qiagen) was added to the mixture. The reactions were incubated for 1 h at 4 °C, then centrifuged at 3,000g for 1 min. The supernatant was incubated again with 10 µl of Ni-NTA agarose resin for 30 min at 4 °C. After centrifugation, the supernatant containing the ubiquitinated poly-SUMO2 chains was used in deubiquitinase assays or frozen at -80 °C.
In vitro deubiquitinase assay. 5 µg Ub 3-7 K48 or K63 chains (Boston Biochem) or 15 µl ubiquitinated poly-SUMO2 chains was incubated with His-USP7 (5-20 nM, Boston Biochem), His-USP1/His-UAF1 (20 nM, Boston Biochem) or no enzyme, in 100 mM Tris, pH 7.5, 200 mM NaCl, 6 mM EDTA, 10 mM DTT and 0.1% Tween-20 at 37 °C for 2 h. The assays were performed in a final volume of 40 µl. The reaction was stopped by the addition of loading buffer and heating at 70 °C for 10 min.
Immunoprecipitation. 500 µg nuclear extract at 1 mg/ml in 50 mM Tris, pH 7.9, and 200 mM NaCl was centrifuged for 10 min at 20,000g at 4 °C, and the supernatant was incubated with specific antibodies at 4 °C overnight. The samples were then centrifuged for 10 min at 20,000g at 4 °C, and Protein G Dynabeads (Invitrogen), preblocked in the presence of 1 mg/ml BSA, were added to the supernatant. After a 1-h incubation at 4 °C, the beads were washed five times with 50 mM Tris, pH 7.9, 200 mM NaCl and 0.05% IGEPAL CA630 (Sigma). Proteins were eluted in SDS loading buffer.
Fluorescence microscopy and high-throughput microscopy. For immunofluorescence of PCNA and SUMO2/3, soluble proteins were preextracted by mild detergent permeabilization with CSKI buffer (10 mM PIPES, pH 6.8, 100 mM NaCl, 300 mM sucrose, 3 mM MgCl 2 , 1 mM EGTA, and 0.5% Triton X-100) before fixation.
For high-throughput microscopy, cells were grown on µCLEAR 96-well plates (Greiner Bio-One), and immunofluorescence was performed with standard procedures. Analysis of DNA replication by EdU incorporation was performed with Click-It (Invitrogen), per the manufacturer's instructions. In all cases, images were automatically acquired from each well with an Opera High-Content Screening System (Perkin Elmer). A 20× magnification lens was used, and images were taken at nonsaturating conditions. Images were segmented with DAPI signals to generate masks matching cell nuclei from which the mean signals for the rest of the stains were calculated. Data were plotted with Prism software (GraphPad)
Quantitative proteomics for factors enriched at nascent DNA molecules with iTRAQ. Filter-aided sample preparation (FASP) and peptide labeling. Eluates were dissolved in 8 M urea in 0.1 M triethylammonium bicarbonate TEAB (UA), and samples were digested with the FASP method 68 with some modifications. Briefly, each sample was loaded onto centrifugal devices Microcon-30 (Merck Millipore). Filters were washed with UA, and proteins were alkylated with 50 mM iodoacetamide for 20 min in the dark. The excess of alkylation reagents was washed out with UA. Proteins were digested overnight with endoproteinase Lys-C from Acromobacter lyticus M497-1 (Wako). Trypsin (Promega) was added, and samples were subjected to a second digestion for 5 h. Each tryptic digest was labeled according to the manufacturer's instructions (ABSciex) with one isobaric amine-reactive tag as follows: Tag114, thymidine fraction; Tag116, EdU fraction; Tag117, EdU+USP7i fraction. After a 1-h incubation, labeled samples were pooled and evaporated to dryness. The iTRAQ sample was cleaned up with a Sep-Pak C18 cartridge for solid-phase extraction (Waters), and eluted peptides were vacuum-dried.
Peptide fractionation by strong anion exchange (SAX). We separated iTRAQlabeled peptides by SAX as described previously 69 , with some modifications. The column was assembled by stacking three layers of 3M Empore Anion Exchange disk (Varian) into a 200-µl micropipette tip. Equilibration and elution were performed in Britton and Robinson buffer (20 mM acetic acid, 20 mM phosphoric npg acid and 20 mM boric acid titrated with NaOH to the following pH values: 11, 8, 6, 5, 4 and 2). Peptides were loaded onto the columns in 100 µl of pH 11 and eluted with the buffers of six different pH values. Eluted peptides were bound to StageTips as described previously 70 . Peptides were eluted from the StageTips before LC-MS/MS with 80% acetonitrile. After SAX separation, the six fractions were evaporated to dryness and resuspended in 10 µl of 0.1% formic acid (FA).
Mass spectrometry analysis. All samples were analyzed with a QqTOF MaXis Impact mass spectrometer (Bruker Daltonics) coupled to a nanoLC Ultra system (Eksigent) equipped with a CaptiveSpray nanoelectrospray ion source supplemented with a CaptiveSpray nanoBooster operated at 0.2 bar/minute, with isopropanol as dopant. Two technical replicates (5 µl) from each SAX fraction were injected into the mass spectrometer. Samples were loaded onto a reversed-phase C18, 5 µm, 0.1 × 20 mm trapping column (NanoSeparations) and washed for 15 min at 2.5 µl/min with 0.1% FA. Peptides were eluted at a flow rate of 300 nl/min onto a homemade analytical column packed with ReproSil-Pur C18-AQ beads, 3 µm, 75 µm × 50 cm, heated to 45 °C. The following gradient was used: 0-2 min, 2% B; 2-133 min, 6-30% B; 133-133.5 min, 30-98% B; 133.5-143.5 min, 98% B; 144-150 min, 2% B (solvent A, 4% can and 0.1% FA; solvent B, acetonitrile and 0.1% FA).
The MS acquisition time used for each sample was 150 min. The QqTOF Impact was operated in a data-dependent mode. The spray voltage was set to 1.35 kV (1868 nA), and the temperature of the source was set to 180 °C. The MS survey scan was performed at a spectrum rate of 2.5 Hz in the TOF analyzer, scanning a window between 80 and 1,600 m/z. The minimum MS signal for triggering MS/MS was set to a normalized threshold of 500 counts. The 30 most abundant isotope patterns with charge ≥2 and m/z >350 from the survey scan were sequentially isolated with an isolation window of 2 m/z and fragmented in the collision cell by collision-induced dissociation (CID) (collision energy of 23-56 eV as a function of the m/z value). The m/z values triggering MS/MS with a repeat count of 1 were placed on an exclusion list for 30 s with the rethinking option: the precursor intensities were reevaluated in the scan (n) regarding their values in the previous scan (n -1). Any m/z with intensity exceeding five times the measured value in the preceding survey scan was reconsidered for MS/MS. Data acquired were transformed to MGF format with the Compass DataAnalysis program. For each MS/MS spectrum, the 400 most abundant nondeconvoluted ions exceeding a threshold of 100 counts were exported and recorded.
Mass spectrometry data analysis. The MGF files were processed with Proteome Discoverer (version 1.4.1.14) against a human database (SwissProt canonical, 20,584 sequences, December 2014 release) including common laboratory contaminant proteins. Oxidation of methionines and tyrosine labeling with iTRAQ4plex reagent were set as variable modifications, whereas lysine and N-terminal labeling with iTRAQ-4plex reagent and cysteine carbamidomethylation were considered to be fixed modifications in the SequestHT search engine. Precursor and fragment mass tolerances were 20 p.p.m. and 0.025 Da. The minimum peptide length was six amino acids with a maximum of two missed cleavages. Peptides were filtered at 1% false discovery rate (FDR) with Percolator. Results were exported into Microsoft Excel for manual data interpretation, and visualization was carried out with Perseus software.
